期刊文献+

短期使用苯海索对服用利培酮治疗精神分裂症患者认知功能影响的对照研究 被引量:9

A control study on short time using benzhexol impact on cognition function of schizophrenia treated with risperidone
下载PDF
导出
摘要 目的:探讨短期使用苯海索对精神分裂症患者认知功能的影响。方法:采用随机、双盲、安慰剂对照研究,将96例因单用利培酮治疗后产生锥体外系反应(EPS)的精神分裂症患者分为研究组(给予苯海索4 mg/d)49例和对照组(给予安慰剂4 mg/d)47例,观察4周。于治疗前后采用MATRICS认知功能成套测验(MCCB)评估认知功能;Barnes静坐不能分级量表(BARS)、Simpson-Angus分级量表(SAS)以及EPS严重度临床总体印象量表(CGI-S-E)评估EPS。结果:两组MCCB的持续操作测验得分治疗前后差值比较,研究组优于对照组,差异有统计学意义(t=2.45,P<0.05)。治疗4周,MCCB的符号编码、迷宫、视觉记忆、持续操作得分增加,具有时间效应(F=4.333,F=15.520,F=4.766,F=11.000;P<0.05或P<0.01)。结论:短期、小剂量苯海索能有效改善抗精神病药治疗引起的EPS,并能提高患者的注意力,改善认知功能。 Objective:To explore short time using benzhexol impact on cognition function with schizophrenia having extrapyramidal symptoms.Method:A randomized double-blind controlled trial of benzhexol( n = 49) versus placebo( n = 47) was conducted in 96 patients with schizophrenia having extrapyramidal symptoms( EPS) by the single use of risperidone and the treatment lasted four weeks with 4 mg / d.Cognition function was assessed by MATRICS consensus cognitive battery( MCCB).Extrapyramidal symptoms were assessed by Barnes akathisia rating scale( BARS),Simpson Angus scale( SAS) and clinical global impression,severity of EPS( CGI-S-E).Results:The score of sustained attention test( CPT-IP) decline of benzhexol group was better than the control.There was difference in the score of CPT-IP decline between two groups( t = 2.45,P〈0.05).The scores of encoding symbol,maze,visual memory and CPT-IP improved after four weeks treatment and had time main effect( F = 4.333,F = 15.520,F = 4.766,F = 11.000;P〈0.05 or P〈0.01).Conclusion:Low dose and short time using of benzhexol is effective in the treatment of extrapyramidal symptoms by risperidone and can improve attention as well.
出处 《临床精神医学杂志》 2015年第6期369-372,共4页 Journal of Clinical Psychiatry
基金 "重大新药创制"科技重大专项(2012ZX09303-003) 上海市卫生和计划生育委员会科研课题(2010083) 上海市精神卫生中心科研课题(2012-YJ-04)
关键词 精神分裂症 认知功能 苯海索 利培酮 schizophrenia cognition function benzhexol risperidone
  • 相关文献

参考文献8

  • 1Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial[ J]. Br J Psychiatry,2008, 193:279-288.
  • 2Stmus RD, Kupehik M, Roitman S, et al. Comparison between ris- peridone,olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study[ J]. Hum Psychopharmaco1,2006,21:235-243.
  • 3Marder SR, Fenton W. Measurement and treatment research to im- prove cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schiz- ophrenia[ J]. Schizophr Res,2004 ,72 :5-9.
  • 4沈渔邮.精神病学[M].北京:人民卫生出版社2009(5).
  • 5Dickinson D, Iannone VN, Wilk CM, et al. General and specific cognitive deficits in schizophrenia [ J ]. Biol Psychiatry, 2004,55 : 826-833.
  • 6Saykin A J, Shtasel DL, Gut RE, et al. NeurepsyeholagieM deficits in neuroleptic naive patients with first-episode schizophrenia [J]. Archives of General Psychiatry ,1994,51:124-131.
  • 7Riedel M, spellman I, strassning M, et al. Effects of risperidone and quetipine on cognition in patients with schizophrenia and predomi- nantly negative symptoms[ J]. Eur Acta Psychiatry Clin Nenrosci, 2007,257:360-370.
  • 8Buchanan RW, Freedman R, Javit DC, et al. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia [ J ]. Schizophr Bul, 2007,33 : 1120-1130.

共引文献45

同被引文献104

引证文献9

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部